Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction
December 16, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 09, 2021 02:00 ET | Verona Pharma plc
Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021ENHANCE Phase 3 program on track to report top-line data in 2022Conference call today at 9:00 a.m....
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces November 2021 Investor Conference Participation
November 01, 2021 03:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
October 26, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
October 13, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
September 02, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
August 31, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021 02:00 ET | Verona Pharma plc
ENHANCE Phase 3 program on track to report top-line data in 2022 Up to $219 million strategic collaboration with Nuance Pharma in Greater China Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces August 2021 Virtual Investor Conference Participation
July 27, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
July 22, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...